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A prespecified subgroup analysis of a 44-week open-
label extension study is presented. The efficacy
and safety of the combination of amlodipine (AML)þ
olmesartan medoxomil (OM), with and without the
addition of hydrochlorothiazide (HCTZ), were investi-
gated in patients aged X65 and o65 years, Blacks and
non-Blacks and patients with and without type 2
diabetes. After an 8-week double-blind, placebo-con-
trolled portion of the study, patients initiated therapy on
AML 5þOM 40mg per day, were uptitrated stepwise to
AML 10þOM 40mg per day, with the addition of HCTZ
12.5mg, and 25mg if blood pressure (BP) goal was not
achieved (o140/90 or o130/80mmHg for patients with
diabetes). Endpoints included the change from baseline
in mean seated systolic BP, mean seated diastolic
BP and achievement of BP goal. BP decreased from
baseline for all treatments in each prespecified sub-
group. By the end of the study, BP goal was achieved in
61.0% of patients aged X65 years, 68.1% of patients
aged o65 years, 63.3% of Blacks, 67.8% of non-Blacks,
26.9% of patients with diabetes and 72.9% of patients
without diabetes. The combination of AMLþOM±HCTZ
was efficacious, safe and well tolerated by these
subgroups.
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Introduction
Hypertension accounts for nearly 7.1 million deaths
worldwide every year and is one of the major causes
of cardiovascular disease.
1 Mortality from ischemic
heart disease and stroke doubles with every
20mmHg systolic blood pressure (SBP) or 10mmHg
diastolic BP (DBP) increase through the BP range
of 115/75 to 185/115mmHg.
2 For this reason, the
Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation and Treatment of
High Blood Pressure (JNC 7) recommended that
antihypertensive therapy be initiated with two
antihypertensive drugs in patients with SBP
420mmHg or DBP 410mmHg above recom-
mended goal levels.
3 The need to treat BP aggres-
sively with two or more antihypertensive drugs to
achieve BP control has been underscored by recent
randomized controlled outcome trials of antihyper-
tensive treatment such as Antihypertensive and
Lipid-Lowering treatment to prevent Heart Attack
Trial (ALLHAT),
4 Valsartan Antihypertensive Long-
term Use Evaluation (VALUE),
5 Anglo-Scandinavian
Cardiac Outcomes Trial (ASCOT),
6 and Avoiding
Cardiovascular events through Combination therapy
in Patients Living with Systolic Hypertension
(ACCOMPLISH).
7 In these studies, excellent BP
control was achieved with two or more drugs, and
only a small minority of patients (none in ACCOM-
PLISH,
7 by design) were able to remain on mono-
therapy throughout the course of the trials. The need
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www.nature.com/jhhfor multiple drug therapy is particularly relevant for
difficult-to-treat patients such as those aged X65
years, Blacks and patients with diabetes mellitus, or
those with multiple risk factors that require a more
rigorous treatment goal of o130/80mmHg.
The Combination of Olmesartan Medoxomil
and Amlodipine Besylate in Controlling High BP
(COACH) study showed that the calcium channel
blocker (CCB) and angiotensin receptor blocker
(ARB) combination of amlodipine (AML) and olme-
sartan medoxomil (OM) had significantly greater
efficacy in reducing SBP and DBP after 8 weeks of
therapy compared with monotherapy with either
compound.
8 In the COACH study, AMLþOM (10
þ20 or 10þ40mg per day) enabled mean seated
SBP (SeSBP) reductions from baseline of over
30mmHg in patients with Stage 2 hypertension
and over 40mmHg in patients with SeSBP
X180mmHg at baseline.
9 In the same study, an
analysis of patients stratified into prespecified
subgroups based on age, race and diabetes status
showed that AMLþOM (10þ40mg per day) en-
abled SeSBP reductions from baseline in the range
of 29 to 34mmHg.
10
An analysis is reported here of the long-term
efficacy and safety of the combination of AMLþ
OM with and without hydrochlorothiazide (HCTZ)
in a 44-week open-label extension (OLE) of the
COACH cohort, in prespecified subgroups including




This was a 44-week OLE of an 8-week multicenter,
randomized, double-blind, placebo-controlled, fac-
torial design study (Figure 1). The study was con-
ducted in accordance with the institutional review
board regulations, the Declaration of Helsinki
and good clinical practice guidelines. All patients
provided written informed consent at screening.
All medications were provided to patients free of
charge. The results of the 8-week double-blind
study, including study population, inclusion and
exclusion criteria, study design, efficacy variables,
safety variables and statistical analyses, have been
published elsewhere.
8 Briefly, for entry into the
8-week double-blind study, patients had a mean
SeDBP of 95 to 120mmHg, and a difference of
p10mmHg between the visit before randomization
and the randomization visit. This report deals
with the portion of the study designed to emulate
clinical practice by titrating patients to JNC 7
treatment guideline goals while assessing long-term
efficacy and safety.
After completion of the 8-week double-blind
portion of the study,
8 all patients who enrolled into
the OLE were switched to the combination of AML
5mgþOM 40mg per day. Patients whose BP was
not adequately controlled (defined as BP o140/90
or o130/80mmHg in patients with diabetes) after
2 weeks were titrated to AML 10mgþOM 40mg.
Subsequent titrations for inadequate BP control
included the addition of HCTZ 12.5mg and then
25mg per day. Subjects with adequately controlled
BP were maintained at the titrated drug doses.
Patients were instructed and reinforced to take their
medication at the same time each day, preferably in
the morning, though treatment accountability was
not assessed at each visit during the OLE of the
study. Patients who developed hypotension and/or
displayed drug intolerance could be back-titrated at
the investigator’s discretion.
Standardization across investigator sites was
maintained through establishment of a detailed
clinical protocol, and procedures at all sites were
reinforced by routine protocol monitoring by Med-
pace Inc. (Cincinnati, OH, USA).
Study population
Subgroup analyses were prespecified. However, the
study was not powered to show statistically sig-
nificant differences between subgroups. Subgroup
analyses were performed for each of the following
variables: diabetes status (yes/no), race (Black/
non-Black) and age (o65 and X65 years).
Efficacy variables
The efficacy assessments in the OLE included the
mean SeSBP and mean seated DBP (SeDBP) by
scheduled visit week (Week 8 to Week 52), the effect
of dosage titrations or addition of HCTZ on change
in SeSBP and SeDBP, and the number and percen-
tage of patients achieving BP treatment goal (o140/
90 or o130/80mmHg for patients with diabetes) by
scheduled week and treatment regimen and at Week
52/early termination (Week 52/ET).
The Week 52/ET measurement of BP was defined
as the value at the end of the study. For patients who
terminated before Week 52, the last measurement
Figure 1 Design of the COACH study. The results of the double-
blind portion have been reported elsewhere.
8 The open-label
portion of the study started all patients (n¼1684) on amlodipine
(AML) 5mgþolmesartan medoxomil (OM) 40mg per day.
Patients who did not achieve a minimum blood pressure (BP)
goal of o140/90mmHg (or o130/80mmHg for patients with
diabetes) were titrated to AML 10mgþOM 40mg per day then
hydrochlorothiazide (HCTZ) 12.5 or 25mg as required to achieve
BP goal. OLE, open-label extension; SeDBP, seated diastolic BP.
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used in the Week 52/ET summaries. The treatment
titration effect was calculated as the BP value at the
last visit on the new dosing regimen subtracted from
the BP value at the last visit of the previous dosing
regimen.
Safety assessments and evaluation of edema
Safety was monitored by assessing the incidence
of adverse events at each visit. The occurrence and
severity of peripheral edema were assessed at all
scheduled clinic visits using a unique case report
form. When an increase in edema category occurred,
investigators were encouraged to report this as an
adverse event. If peripheral edema was present, the
investigators rated its severity on a case report form
using the following 5-point scale: (0) no edema; (1)
mild pitting edema/slight indentation; (2) moderate
pitting edema/moderate indentation; (3) deep pit-
ting edema/indentation remains and (4) leg remains
swollen. If a patient complained of edema, this
complaint would be reported as an adverse event,
even if the physical assessment did not see a differ-
ence from the previous evaluation (reported inclu-
ding the terms edema; edema, peripheral; pitting
edema; generalized edema and localized edema).
Results
Study population
A total of 1684 patients entered the OLE. The base-
line SeBP without any antihypertensive therapy
was 163.6/101.5mmHg. Mean SeBP was 131.2/81.9
mmHg in the overall population at Week 52/ET,
ad e c r e a s eo f3 2 . 4 m m H gi nS e S B Pa n d1 9 . 6 m m H g
in SeDBP from baseline. At Week 52/ET, 66.7% of
a l lp a t i e n t si nt h eO L Eh a da c h i e v e ds e a t e dB P( S e B P )
goal.
11 Baseline SeBP characteristics for the total
population and selected subgroups (age, race and
diabetes status) are summarized in Table 1, based
















N 436 306 223 328 1340
Baseline 155.8±0.6/100.4±0.2 159.4±0.7/101.4±0.3 163.1±0.9/102.7±0.4 169.7±0.9/103.8±0.3 161.2±0.4/101.9±0.1
Week 52/ET 127.0±0.6/81.5±0.4 130.3±0.7/82.8±0.5 129.8±0.9/82.3±0.6 135.9±0.8/84.4±0.5 130.3±0.4/82.6±0.2
X65 years
N 8 97 26 39 1 3 3 1
Baseline 166.3±1.7/99.9±0.5 166.4±1.6/99.9±0.4 173.7±2.0/100.4±0.4 184.2±1.6/100.9±0.6 173.1±0.9/100.2±0.2
Week 52/ET 130.6±1.8/78.3±0.9 133.8±1.6/80.4±1.0 134.1±1.9/76.5±1.0 140.2±1.8/79.7±0.8 134.8±0.9/78.7±0.5
Race
Black
N 84 90 82 147 409
Baseline 156.1±1.4/100.7±0.6 158.1±1.3/100.9±0.5 161.1±1.6/102.4±0.5 172.3±1.4/103.6±0.5 163.3±0.8/102.2±0.3
Week 52/ET 132.8±1.7/84.0±1.1 130.6±1.4/83.4±0.8 129.6±1.8/82.8±1.0 135.9±1.4/83.7±0.8 132.6±0.8/83.5±0.5
Non-Black
N 441 288 204 272 1262
Baseline 157.9±0.7/100.2±0.2 161.5±0.8/101.2±0.3 167.2±1.0/102.1±0.4 173.2±1.0/102.9±0.3 163.7±0.4/101.3±0.1
Week 52/ET 126.7±0.6/80.4±0.4 131.1±0.7/82.0±0.5 131.2±0.9/80.3±0.6 137.3±0.8/83.3±0.5 130.7±0.4/81.3±0.2
Diabetes status
Yes
N 36 30 44 109 227
Baseline 163.6±3.3/99.8±0.6 159.5±2.1/100.1±0.7 166.4±2.2/101.2±0.7 173.3±1.5/101.6±0.5 168.2±1.1/101.0±0.3
Week 52/ET 130.7±3.2/80.2±1.5 132.8±2.8/82.2±1.1 132.1±2.3/79.3±1.2 136.8±1.4/81.9±0.7 134.0±1.1/81.0±0.5
No
N 489 348 242 310 1444
Baseline 157.2±0.6/100.3±0.2 160.8±0.7/101.2±0.2 165.3±1.0/102.4±0.3 172.7±1.0/103.7±0.3 162.8±0.4/101.6±0.1
Week 52/ET 127.4±0.6/81.1±0.4 130.8±0.7/82.4±0.5 130.5±0.9/81.3±0.6 136.8±0.8/84.0±0.5 130.7±0.4/82.0±0.2
Abbreviations: AML, amlodipine; ET, early termination; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil; SeBP, seated BP; SeDBP, seated
diastolic BP; SeSBP, seated systolic BP.
Data are expressed as mean±standard error of the mean (s.e.m.). Baseline for vital signs was defined as the average of the visit values from the
randomization visit (Week 0) and the visit before the randomization visit (Week  1). Only patients with baseline and Week 52/ET blood pressure
(BP) measurements are included. Each BP visit value is the mean of three measurements. Age was calculated using the date the patient was
randomized.
aThe no. of treatment regimens may not add to all patients due to some patients receiving non-protocol drug combinations, as noted in the
Materials and methods section.
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higher SeSBP in older age and diabetes subgroups
likely reflects the higher prevalence of elevated
SeSBP due to arterial stiffness in these popula-
tions.
12,13 In general, baseline SeSBP was higher in
patients subsequently titrated to the more rigorous
treatment regimens, including HCTZ. There was little
difference in SeDBP at baseline between paired
subgroups.
Effect of age
Mean SeBP decreases for patients aged o65 years
and X65 years were 31.0/19.2 and 38.3/21.5mmHg,
respectively, at Week 52/ET (Figure 2). Baseline
SeBP was highest, and SeBP reductions were great-
er, in patients that were eventually titrated to AML
10mgþOM 40mgþHCTZ 25mg per day (Table 1).
In general, the addition of HCTZ caused numerically
greater SeBP reductions in patients aged X65 years
(Table 1).
In patients aged o65 years, 68.1% (913/1341)
achieved SeBP goal by Week 52/ET, ranging from
47.6 to 81.2% across treatment regimens (Figure 3).
Among patients aged X65 years, 61.0% (202/331)
reached their SeBP goal by Week 52/ET, ranging
from 41.8 to 74.2% across treatment regimens
(Figure 3). Patients aged o65 years had lower
baseline SeBP levels and thus were more likely
to reach SeBP goals compared with patients aged
X65 years.
The effect of treatment titration was also investi-
gated (Figure 4). Patients aged X65 years had
greater reductions in SeSBP at each titration step,
compared with patients aged o65 years (Figure 4).
At each titration step, mean SeSBP decreases
were 2.2mmHg greater for patients aged X65 than
patients aged o65 years. Uptitration produced
similar mean reductions in SeDBP (B5.1mmHg)
at each dose in patients aged o65 years and X65
years (Figure 4).
Effect of race
Both the Black and the non-Black subgroups had
clinically relevant SeBP decreases from baseline by
Week 52/ET (Figure 2). Mean SeBP decreases at
Week 52/ET for Black and non-Black patients were
30.8/18.7 and 33.0/20.0mmHg, respectively. The
baseline SeBP was highest, and the SeSBP reduc-
tions were greatest, in patients titrated to AML
10mgþOM 40mgþHCTZ 25mg per day (Table 1).
Figure 2 Reductions in seated blood pressure (SeBP) at Week 52/early termination in all patients and by subgroup. SeDBP, seated
diastolic BP; SeSBP, seated systolic BP.
Figure 3 Patients achieving blood pressure (BP) goal at Week 52/early termination, by subgroup and treatment regimen. BP goal was
defined as BP o140/90mmHg for patients without diabetes and o130/80mmHg for patients with diabetes. AML, amlodipine; HCTZ,
hydrochlorothiazide; OM, olmesartan medoxomil.
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and 67.8% (856/1263) of non-Black patients in the
OLE achieved the SeBP goal, although more Black
patients were titrated to higher dosages. Approxi-
mately 20% of Blacks remained on the initial dose
of AML 5mgþOM 40mg per day, compared
with 34.9% of non-Blacks (Table 1). In Black
patients, 35.9% were uptitrated to the AML 10mgþ
OM 40mg þ HCTZ 25mg per day dose level, and
49.7% on this dose level achieved their SeBP goal at
Week 52/ET (Figure 3). Of non-Black patients,
82.5% who remained on the initial dose of AML
5mg þ OM 40mg per day achieved their SeBP
goal at Week 52/ET. For non-Black patients titrated
to AML 10mgþOM 40mgþHCTZ 25mg per day,
44.5% reached the SeBP goal at Week 52/ET
(Figure 3).
The mean incremental changes in SeBP due
to dose titration are shown in Figure 4. In Black
patients, the greatest incremental SeBP reductions
were observed in patients switching from AML
10mgþOM 40mgþHCTZ 12.5mg per day to AML
10mgþOM 40mgþHCTZ 25mg per day, and in
non-Black patients, incremental SeBP reductions
were similar for all dose titrations.
Effect of diabetes status
At Week 52/ET, SeBP reductions from baseline in
patients with diabetes were 34.2/19.9mmHg com-
pared with 32.1/19.6mmHg in patients without
diabetes (Figure 2). At Week 52/ET, 26.9% (61/227)
of patients with diabetes achieved the strict SeBP goal
of o130/80mmHg and 72.9% (1054/1445) of patients
without diabetes achieved their SeBP goal of
o140/90mmHg. By Week 52/ET, 48.0% of patients
with diabetes were titrated to AML 10mgþOM
40mgþHCTZ 25mg per day and 21.1% (23/109)
achieved an SeBP goal of o130/80mmHg (Figure 3).
Uptitration of treatment from AML 10mgþOM
40mgþHCTZ 12.5mg per day to AML 10mgþOM
40mgþHCTZ 25mg per day resulted in the greatest
SeBP reductions, irrespective of diabetes status
(Figure 4). Reductions in SeSBP in patients with
diabetes ranged from 5.2 to 9.5mmHg, and reduc-
tions in SeDBP ranged from 3.0 to 4.6mmHg
(Figure 4). Reductions in SeSBP in patients without
diabetes ranged from 7.7 to 10.1mmHg, and reduc-
tions in SeDBP ranged from 4.9 to 6.5mmHg.
Safety
This OLE study did not identify any safety concerns
that had not previously been identified in the 8-week
double-blind study.
8 The adverse event profiles pre-
sented by the patients were those expected for each
component monotherapy independently. There did not
appear to be any unexpected drug-related adverse
events with any combination of treatment regimens in
any of the subgroups (data not shown). As reported
earlier,
11 peripheral edema, a known side effect of the
use of AML,
14 was lower during the OLE compared
with the double-blind portion.
8 Specifically, drug-
related edema occurred in 7.0, 11.1, 9.1 and 10.7% of
patients receiving AML 5mgþOM 40mg per day,
AML 10mgþOM 40mg per day, AML 10mgþOM
40mgþHCTZ 12.5mg per day and AML 10mgþOM
40mgþHCTZ 25mg per day, respectively.
11
Figure 4 Effect of dosage titration and regimen change on blood pressure (BP). (a) Effect of titration on seated systolic BP (SeSBP).
(b) Effect of titration on seated diastolic BP (SeDBP). Data are mean±standard error of the mean. AML, amlodipine; HCTZ,
hydrochlorothiazide; OM, olmesartan medoxomil.
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This OLE of the COACH study used a titrate-to-
goal scheme to more accurately resemble current
recommendations and clinical practice.
15,16 After
completion of the 8-week double-blind period, all
patients enrolled in the 44-week OLE started
on AML 5mgþOM 40mg per day, and if BP goal
was not met, they could be titrated to the next dose
level of the study. This design allowed for assess-
ment of the effectiveness of the component therapies
as well as showing how well investigative sites
therapeutically treated their patients with the
objective of having them reach JNC 7-defined BP
goals of o140/90 or o130/80mmHg for patients
with diabetes.
3
The main finding of the OLE of COACH is that the
antihypertensive effects of AMLþOM±HCTZ regi-
mens were well maintained during the 44-week
follow-up period in all three patient subgroups
whose hypertension is generally considered diffi-
cult-to-treat. Importantly, titration to higher dosages
of OMþAML, and the addition of HCTZ, resulted in
greater SeBP reductions with each titration step. The
achievement of SeBP goals was higher at Week 52/
ET than in the 8-week double-blind portion of the
study in all patient subgroups and for all drug
combinations, indicating the value of adding a third
antihypertensive agent. The incremental improve-
ments in BP control throughout the OLE period were
attributable to the algorithmic treatment plan.
The excellent SeBP goal attainment in the OLE of
COACH was achieved despite the fact that some
investigators did not titrate to the next dose level in
patients with SeBP above treatment goal, as required
by the study protocol. Failure to add medications or
increase dosages of existing medications when
treatment goals remain unmet is termed ‘clinical
inertia’ and is thought to account for as much as
B20% of failure to achieve BP control in clinical
practice.
17,18 Clinical inertia also occurs in clinical
trials and even when patients are compliant with
their therapy.
19 Clinical inertia was manifest in the
OLE of the COACH study, as at the end of the study
(Week 52/ET), 20% of patients who remained on
AML 5mgþOM 40mg per day had not achieved
their SeBP goal and were candidates for titration
therapy that was never administered.
11 It is likely
that control rates would have been even higher
had the titration scheme specified in the protocol
been followed more closely. In addition, it is also
possible that patients uptitrated to AML 10mgþOM
40mgþHCTZ 25mg per day and still not at BP goal
may have had resistant hypertension and were
unable to respond to a combination of three
antihypertensive drugs.
Overall, BP control in each of the difficult-to-treat
subgroups studies analysed in the OLE of COACH
was greater than that reported in the National Health
and Nutrition Examination Survey (NHANES).
20
The overall percentage of patients aged X65 years
achieving their BP goal at Week 52/ET on combina-
tions of AMLþOM was 61.0%. It is well known that
as age increases, hypertension is often harder to
control.
21 The high BP goal achievement in the X65
years of age patient subgroup supports the use of
combination AMLþOM±HCTZ therapy in the el-
derly.
Similar benefits were observed in Black patients,
63.3% of whom achieved BP goal at Week 52/ET
using combinations of AMLþOM±HCTZ. These
data support the use of AMLþOM±HCTZ in Black
patients with hypertension.
Nearly 27% of patients with diabetes achieved the
American Diabetes Association-recommended BP
goal of o130/80mmHg,
3 though slightly lower than
the goal rate in the NHANES report (37.5%).
20 The
challenge of achieving this strict SeBP goal of o130/
80mmHg is reflected by the higher dose levels to
which patients with diabetes were titrated: in this
study, 48% of patients with diabetes were titrated to
AML 10mgþOM 40mgþHCTZ 25mg per day, and
only 21.1% of this group achieved the stringent
SeBP goal of o130/80mmHg at Week 52/ET. The
mean SeBP achieved at Week 52/ET increased with
each titration step, likely due to the fact that, in
general, titration was only needed in subjects where
the baseline SeBP was higher initially. Conse-
quently, the change from baseline in SeSBP was
greater with the higher doses of component drugs
and with the triple drug regimen, reinforcing
recommendations that patients with SeSBP
X20mmHg above goal initiate combination therapy
as a first step.
3,22
Combinations of antihypertensive drugs with
different mechanisms of action, such as an ARB
(OM) added to a dihydropyridine CCB (AML)
8 or
to a thiazide diuretic (HCTZ)
23 have been shown
to have additive effects on BP and may even
ameliorate adverse effects that are specific for the
component monotherapies.
24–26 In this study, the
similar adverse event profiles across treatment
regimens and within subgroups support this con-
clusion. Dihydropyridine CCBs and thiazide diure-
tics decrease BP through reduction of peripheral
vascular resistance and induction of natriuresis,
respectively, which activate the renin-angiotensin-
aldosterone system, thus decreasing their BP-low-
ering effects. However, this is counteracted by the
addition of ARBs that block the action of angioten-
sin II at the AT1 receptor, further inducing addi-
tional vasodilation, sodium and water excretion and
BP reduction.
25,27
In conclusion, the 44-week, OLE of the COACH
study showed that long-term administration of the
combination of AMLþOM±HCTZ is efficacious, safe
and well tolerated in difficult-to-treat subgroups of
patients with hypertension. The regimen of multiple
hypertensive therapies with differing mechanisms of
action provides additive benefit in BP control and
achievement of guideline-recommended BP goals
without compromising patient safety.
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